Kyriakos P Papadopoulos

Kyriakos P Papadopoulos

UNVERIFIED PROFILE

Are you Kyriakos P Papadopoulos?   Register this Author

Register author
Kyriakos P Papadopoulos

Kyriakos P Papadopoulos

Publications by authors named "Kyriakos P Papadopoulos"

Are you Kyriakos P Papadopoulos?   Register this Author

65Publications

2451Reads

32Profile Views

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.

N Engl J Med 2018 07 4;379(4):341-351. Epub 2018 Jun 4.

From the Departments of Dermatology and Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston (M.R.M.), and South Texas Accelerated Research Therapeutics (START), San Antonio (K.P.P.) - both in Texas; the Department of Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC (D.R., A.A.T.), the Department of Medical Oncology, Royal North Shore Hospital, St. Leonards, VIC (A.G.), the Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth, WA (A.M.L.), and Royal Brisbane and Women's Hospital and University of Queensland, Brisbane (B.G.M.H.) - all in Australia; the Department of Dermatology, Brigham and Women's Hospital (C.D.S.), the Department of Dermatology, Harvard Medical School (C.D.S.), and the Department of Medical Oncology, Dana-Farber Cancer Institute (G.R.) - all in Boston; Schleswig-Holstein University Hospital, Kiel (A.H.), and University Hospital Essen, Essen and German Cancer Consortium, Essen (D.S.) - both in Germany; University of Colorado Denver, School of Medicine, Aurora (K.D.L.); the Departments of Head and Neck-Endocrine Oncology (C.H.C.) and Cutaneous Oncology (N.I.K.), H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; the Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St. Louis (L.H.-A.); the Department of Dermatology, Stanford University School of Medicine, Redwood City (A.L.S.C.), and the Division of Dermatology, City of Hope, Duarte (B.M.) - both in California; the Department of Medicine, Head and Neck Medical Oncology, Memorial Sloan Kettering Cancer Center, New York (L.A.D.), and Regeneron Pharmaceuticals, Tarrytown (F.S., M.M., K.M., G.D.Y., I.L., M.G.F.) - both in New York; Regeneron Pharmaceuticals, Basking Ridge, NJ (B.G., S.L., J.L., J.B., E.S.); University of Arizona Cancer Center, Tucson (H.M.B.), and Banner MD Anderson Cancer (J.H.) and the Department of Medical Oncology, Banner MD Anderson Cancer Center (J.N.), Gilbert - all in Arizona; Medical Oncology Department, Vall D'Hebron University Hospital (I.B.), and Institut Català D'Oncologia, Oncobell Program (IDIBELL), L'Hospitalet de Llobregat (M.G.-M.), Barcelona, and START Madrid-FJD, Hospital Fundación Jiménez Díaz, Madrid (V.M.) - all in Spain; Sarah Cannon Research Institute, Nashville (M.L.J.); and the Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta (T.K.O.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1805131
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1805131DOI Listing
July 2018

Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.

J Clin Oncol 2016 10;34(29):3562-3569

Aung Naing, Rivka R. Colen, David S. Hong, and Nizar M. Tannir, MD Anderson Cancer Center, Houston; Kyriakos P. Papadopoulos and Drew R. Rasco, START Center for Cancer Care, San Antonio, TX; Karen A. Autio, Memorial Sloan Kettering Cancer Center, New York, NY; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Manish R. Patel, Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Deborah J. Wong, University of California Los Angeles, Los Angeles; Melinda Whiteside, John B. Mumm, Ivan H. Chan, Peter Van Vlasselaer, and Martin Oft, ARMO BioSciences, Redwood City, CA; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Shubham Pant, Oklahoma University, Oklahoma City, OK; and Johanna C. Bendell, Todd M. Bauer, and Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.1106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5657013PMC
October 2016

Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor.

Cancer Chemother Pharmacol 2015 May 27;75(5):887-95. Epub 2015 Feb 27.

South Texas Accelerated Research Therapeutics, 4383 Medical Drive, Suite 4021, San Antonio, TX, 78229, USA,

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-015-2712-0
Publisher Site
http://dx.doi.org/10.1007/s00280-015-2712-0DOI Listing
May 2015

Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.

J Clin Oncol 2015 Mar 15;33(7):732-9. Epub 2014 Sep 15.

Kyriakos P. Papadopoulos and Joseph R. Holahan, South Texas Accelerated Research Therapeutics, San Antonio, TX; David S. Siegel and David H. Vesole, John Theurer Cancer Center, Hackensack, NJ; Peter Lee, Tower Cancer Research Foundation, Beverly Hills; Naseem Zojwalla, Susan Lee, and Zhengping Wang, Onyx Pharmaceuticals, South San Francisco, CA; Steven T. Rosen, Northwestern Medical Center, Chicago, IL; and Ashraf Badros, Greenebaum Cancer Center, University of Maryland, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.52.3522DOI Listing
March 2015

A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors.

Invest New Drugs 2014 Aug 7;32(4):653-60. Epub 2014 Mar 7.

University of Colorado School of Medicine and Developmental Therapeutics Program, University of Colorado Cancer Center, Mail Stop 8117, RC1 South, Rm 8123, 12801 E. 17th Avenue, Aurora, CO, 80045, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-014-0071-zDOI Listing
August 2014

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.

Clin Cancer Res 2014 May 28;20(9):2445-56. Epub 2014 Feb 28.

Authors' Affiliations: South Texas Accelerated Research Therapeutics, San Antonio, Texas; Memorial Sloan-Kettering Cancer Center, Memorial Hospital, New York, New York; Sanofi, Cambridge, Massachusetts; Exelixis Inc., South San Francisco, California; Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain; Monash Institute of Medical Research, Monash University, Melbourne, Victoria, Australia; and Sanofi, Vitry-sur-Seine, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-2403DOI Listing
May 2014

A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors.

Cancer Chemother Pharmacol 2013 Oct 25;72(4):861-8. Epub 2013 Aug 25.

South Texas Accelerated Research Therapeutics (START), 4383 Medical Dr, Room 4042, San Antonio, TX, 78229, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2267-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784064PMC
October 2013

A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma.

Cancer 2012 Jun 17;118(12):3128-34. Epub 2011 Oct 17.

Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.26510DOI Listing
June 2012

Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.

Clin Cancer Res 2009 Jun 19;15(11):3866-71. Epub 2009 May 19.

Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-08-2373DOI Listing
June 2009

A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies.

Clin Cancer Res 2008 Nov;14(21):7110-5

Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-08-0483DOI Listing
November 2008

Future options for imatinib mesilate-resistant tumors.

Expert Opin Investig Drugs 2007 Oct;16(10):1549-60

Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.16.10.1549DOI Listing
October 2007

Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival.

Clin Gastroenterol Hepatol 2007 Apr 26;5(4):508-12. Epub 2007 Mar 26.

South Texas Veterans Health Care System, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S154235650700105
Publisher Site
http://dx.doi.org/10.1016/j.cgh.2007.01.014DOI Listing
April 2007

Current chemotherapy options for thymic epithelial neoplasms.

Expert Opin Pharmacother 2005 Jun;6(7):1169-77

Cancer Therapy and Research Center, Institute for Drug Development, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.6.7.1169DOI Listing
June 2005

Renal medullary carcinoma: case report and review of the literature.

Am J Clin Oncol 2003 Oct;26(5):489-92

Division of Medical Oncology, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York, USA.

View Article

Download full-text PDF

Source
https://insights.ovid.com/crossref?an=00000421-200310000-000
Publisher Site
http://dx.doi.org/10.1097/01.coc.0000037663.61643.5ADOI Listing
October 2003

Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting.

J Clin Invest 2002 Dec;110(12):1813-22

Ludwig Institute Clinical Trial Center, New York Branch at Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/JCI16428DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC151653PMC
December 2002